



HHS Public Access

Author manuscript

Compr Psychiatry. Author manuscript; available in PMC 2017 February 01.

Published in final edited form as:

Compr Psychiatry. 2016 February ; 65: 15–23. doi:10.1016/j.comppsy.2015.09.007.

Psychometric properties of the DY-BOCS in a Turkish sample of children and adolescents

Ay egül Selcen Güler, M.D.,

Cumhuriyet University Faculty of Medicine, Department of Child and Adolescent Psychiatry, Sivas, Turkey

Maria Conceição do Rosário, M.D.,

Associate Professor, Federal University of São Paulo, Department of Child and Adolescent Psychiatry, São Paulo, Brazil

Ay e Burcu Ayaz, M.D.,

Sakarya Training and Research Hospital, Sakarya, Turkey

Sebla Gökçe, M.D.,

Erenköy Hospital for Mental Health, İstanbul, Turkey

Yasemin Yulaf, M.D.,

Tekirda Training and Research Hospital, Tekirda , Turkey

Senem Ba gül, M.D.,

Göztepe Training and Research Hospital, İstanbul, Turkey

Özlem Özcan, M.D.,

Associate Professor, İstanbul University Faculty of Medicine, Department of Child and Adolescent Psychiatry, Malatya, Turkey

Koray Karabekiro lu, M.D.,

Associate Professor, Ondokuz Mayıs University Faculty of Medicine, Department of Child and Adolescent Psychiatry, Samsun, Turkey

Kerim Munir, M.D., M.P.H, D.Sc.,

Associate Professor, Boston Children's Hospital, Division of Developmental Medicine, Boston, MA, USA

Lütfullah Be iro lu, M.D., and

Professor, Katip Çelebi University Faculty of Medicine, Department of Psychiatry, İzmir, Turkey

Corresponding author: Ay egül Selcen Güler, Present address: Beykent University, Department of Psychology, 34396 Ayaza a-Maslak/Istanbul, Turkey, selcenguler@yahoo.com.

Declaration of Conflicts of Interest

The author(s) declared the following potential conflicts of interest: Dr. Maria Conceição do Rosário has acted as a speaker for Novartis, Shire and Abbott in the last three years. Dr. Yankı Yazgan received fees as an advisory board member and a speaker for Janssen Cilag, Turkey, Eli Lilly, Turkey, and Bristol Myers Squibb, Turkey in the last 5 years.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Yankı Yazgan, M.D.

Marmara University Faculty of Medicine, Department of Child and Adolescent Psychiatry, Istanbul, Turkey

Abstract

Background—Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) is a promising scale for assessing frequency and severity of symptom dimensions. The main objective of the study was to assess the psychometric properties of the DYBOCS in a large sample of children and adolescents from Turkey.

Methods—We studied 143 children and adolescents, 7–18 years, with well characterized DSM-IV-R OCD, ascertained from seven collaborating university or state hospital sites. We compared the DYBOCS scores with the Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS), the Children's Depression Inventory (CDI), the Yale Global Tic Severity Scale (YGTSS) and the Child Behavior Checklist-6-18 years (CBCL-6-18).

Results—The internal consistency of the DY-BOCS symptom dimensions and inter rater agreement of component scores were excellent. The agreement between global DY-BOCS score and the total CY-BOCS score was highly significant (Pearson $r = 0.55$, $p < 0.0001$). Severity scores for individual symptom dimensions were independent of one another, only modestly correlating with the global ratings, and were also differentially related to ratings of depression, anxiety and tic severity.

Conclusion—The DY-BOCS is a reliable and valid instrument for assessing multiple aspects of OCD symptom severity in children and adolescents from Turkey.

Keywords

obsessive-compulsive disorder; obsessive-compulsive symptom dimensions; validity; reliability; psychometric properties; DY-BOCS

Introduction

Obsessive compulsive disorder (OCD) is a chronic condition affecting 1%–3% of the global population.^{1–3} OCD affects children, adolescents and adults and has a marked disabling influence on the lives of many people worldwide.³ The disorder is characterized by obsessions (defined as persistent distressing, intrusive, and unwanted thoughts, fears or images) and/or compulsions (defined as ritualized behaviors or mental acts, performed to relieve the distress caused by the obsessions).^{4,5} As of May 2013, the DSM-5⁵ excluded OCD from the anxiety disorders and created the OCD spectrum disorders.

Subjects with OCD exhibit remarkably heterogeneous symptoms with a complex overlap between obsessive-compulsive (OC) symptom dimensions.^{6,7} In DSM-5,⁵ the issue of heterogeneity remains unresolved but is acknowledged that the dimensional perspective may help to unresolve this issue.⁸ Numerous studies have described a four or five factor solution to better describe the OC symptom dimensionality.^{6,9} Furthermore, there is support for OC symptom dimensionality among child^{10,11} and adult samples,^{12–14} that are temporally

stable,^{15,16} have associations with specific brain regions in neuroimaging studies,^{17–21} and correlate meaningfully with various genetic variables^{22–26} as well as treatment response.^{12,27–30} Therefore, there is a relevant rationale for assessing OC symptom dimensions.

To date, the instruments considered as “gold standard” for assessing OCD include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS). Despite the strengths, these measures have important limitations: for example, obsessions and compulsions rarely occur in isolation, and the “resistance” and “control” items contribute weakly to the overall severity score.³¹ Moreover, the YBOCS and CY-BOCS do not allow the assessment of severity for specific symptom dimensions.

More recently, the Dimensional Yale-Brown Obsessive Compulsive Scale (DY-BOCS) was developed to further assess the presence and severity of specific OC symptom dimensions. The DY-BOCS provides a more detailed description of OC symptoms, divided in six OC symptom dimensions. Developed to better investigate this dimensional approach to OCD, the DYBOCS has many strengths, such as: i) obsessions and compulsions are assessed together, according to their content; ii) it inquires about symptoms that are otherwise inherently ubiquitous (e.g., checking, repetition mental and avoidance compulsions are inquired as part of several dimensions. For instance, checking related to sexual and religious obsessions versus checking related to contamination worries, etc.)³²; iii) the DYBOCS assesment of symptom dimension severity investigates frequency, distress and interference; iv) the DYBOCS global severity includes not only the assessment of symptom severity but also the assessment of the impairment as a result of the symptoms.

The DY-BOCS was initially validated in English and Portugese, with excellent psychometric properties³² and subsequently translated and validated in Spanish,³¹ Chinese,³³ Hungarian,³⁴ Korean³⁵ and Japanese³⁶ with excellent psychometric properties. In summary, the DY-BOCS is noted to be a valid and reliable tool for assessing OC symptom dimensions as well as providing valid overall estimates of symptom severity. To date, these validation studies (apart from the original validation study³²) have been conducted in adult samples.

The main objective of the study was to assess the psychometric properties of the DYBOCS in a large sample of children and adolescents from Turkey. To our knowledge this study is the first analysis of the DY-BOCS in a pediatric sample after the original validation study. Our hypothesis was that DY-BOCS would have excellent psychometric properties.

Method

One hundred and forty-three outpatient OCD subjects, aged 7–18, were recruited from 7 collaborating university and research and training hospital sites in the country: Sivas, n=19; Sakarya, n=30; Erenköy, Istanbul, n=21; Tekirda n=29; Göztepe, Istanbul n=21; Malatya n=18; and Samsun (N=5). The centers developed a network of established child psychiatry units collaborating across the country.

Inclusion criteria were: parental informed consent and child informed assent; DSM-IV OCD criteria, age 7–18 years and an intelligence quotient (IQ) > 70. Exclusion criteria were: head trauma resulting in loss of consciousness, chronic neurological disorder (e.g. epilepsy, cerebral palsy); psychosis, bipolar disorder, autism spectrum, and substance use disorders. Subjects were also excluded if they were concurrently undergoing either cognitive behavior therapy (CBT) and/or using psychotropic medications. All the subjects were assessed for the first time at clinic intake and the study did not impede the subsequent provision of normative care. The project was approved by the respective institutional review boards at each site. After a thorough description of the study and the assurance that their decision to participate would be voluntary and would not interfere with their access to clinical treatment, parents of all patients were asked to sign an informed consent document. Children and adolescents were asked to sign an assent form if they agreed to participate in the study after a detailed description of the study.

Instruments

Clinician-rated instruments

Sociodemographic Questionnaire—This questionnaire included questions about child's age, gender, family income, educational and occupational status of the parents, psychiatric family history in first-degree relatives, child's age at OC symptom onset, child's age when treatment was sought, stressors around time of symptom onset, medical history (including history of frequent infections, and temporal association of any throat infections with onset of tics and/or OC symptoms).

Kiddie-Schedule for Affective Disorders and Schizophrenia for school age children-Present and Lifetime version (K-SADS-PL)—This semi-structured interview based on the DSM-IV criteria was used to investigate OCD and possible co-occurring conditions.³⁷ The reliability and validity of the Turkish version has been established.³⁸

Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)—The CY-BOCS is a 10-item, clinician-rated, semi-structured instrument designed to assess the symptom severity of OCD during a subject's previous week. The CY-BOCS has good psychometric data³⁹ and was used to assess convergent validity. The psychometric properties of the Turkish version of the CY-BOCS have been previously established.⁴⁰

Yale Global Tic Severity Scale (YGTSS)⁴¹—The YGTSS is a semi-structured clinician-rated instrument to assess the presence and severity of motor and vocal tics. Reliability of the Turkish version is available (Zaimo lu S: unpublished data 1995). The presence of motor and vocal tics based on child and parent(s) reports over the previous week and behavioral observations are assessed. Severity scores are based on the number, frequency, intensity, complexity and interference of the tics (range=0–50). A separate, one-item impairment rating is also included that captures distress and impairment in interpersonal, academic, and occupational domains related to the endorsed tics (range=0–50).

Dimensional Yale-Brown Obsession Compulsion Scale (DY-BOCS)³²—The DY-BOCS is a semi-structured interview-based scale for assessing the presence and severity of OC symptom dimensions in two parts: a) an 88-item OC symptom checklist; and b) rating scales for each OC symptom dimension, for the assessment of the impairment caused by the symptoms and an overall estimate of OCD severity. The checklist provides a detailed description of six OC symptom dimensions: (i) *obsessions about harm due to aggression/injury/violence/natural disasters and related compulsions*; (ii) *obsessions concerning sexual / moral /religious thoughts and related compulsions*; (iii) *obsessions about symmetry/ 'just-right' perceptions, and compulsions to count or order/ arrange*; (iv) *contamination obsessions and cleaning compulsions*; (v) *hoarding obsessions and compulsions*; and (vi) *miscellaneous obsessions and compulsions that relate to somatic concerns and superstitions, among other symptoms*.

DY-BOCS Measures—Patients are asked to endorse both lifetime and current symptoms, reviewed by a clinician to ensure that endorsed items meet OC symptom guidelines. Severity of each OC dimension is measured on three ordinal scales with six anchor points that focus on: symptom frequency (0–5); amount of distress they caused (0–5); and the degree to which they interfered with functioning (0–5) during the previous week. The clinicians are required to assess the subject's overall level of current impairment due to OC symptoms on a likert scale (0=none, to 15=severe). *Total global score* (0=30) is obtained by combining the overall symptom severity score (0–15) and the impairment score (0–15).

Parent-rated instruments

Child Behavior Checklist for ages 6–18 (CBCL 6–18)⁴²—This parent-rated CBCL provided information on the index subject's behaviors in the past 6 months (0–2) grouped under subscales. Two general behavior scores are obtained from the scale: Internalizing and Externalizing. These included: withdrawal, somatic complaints, anxiety/depression scores form the internalizing behavior scale; and conduct behavior and aggression subscales form the externalizing behavior scale. There are other subscales assessing social problems, attention problems, and thought problems. Scores of all of the subscales sum up to form the total problem score. The reliability and validity of the Turkish version of CBCL-6-18 is well established.⁴³ In this study we use the CBCL internalizing behavior subscale scores that are known to correlate well with other anxiety scales.^{44–47}

Child-rated instruments

Children's Depression Inventory (CDI)⁴⁸—The CDI is a widely used self-report measure of depressive symptoms in youth, 7–17 years. It consists of 27 items designed to assess symptoms of depression, including sleep disturbance, appetite loss, suicidal thoughts, and general dysphoria. CDI items are scored on a 3-point scale (0–2). Total score is the sum of all item scores. The validity and reliability of the Turkish version of the CDI has been established⁴⁹ with scores >19 signaling need for evaluation for depression.

YGTSS, CDI and CBCL (internalizing symptoms, i.e, withdrawn, anxious/depressive subscales) were used to assess the divergent validity of the component scales of the DY-

BOCS. K-SADS interviews were completed initially to endorse diagnosis of OCD and for identification of co-occurring conditions.

Procedures

Translation of the instruments

The translation of the DY-BOCS from English into Turkish was authorized by the main authors (JFL and MCR) and made by some of the authors (YY, LB and ASG). Later, a native speaker in English did the back-translation into English. The two versions were then compared and inconsistencies resolved. All other instruments had previously been translated into Turkish.

Interviews

Informants included a parent and the child in the assessment room. Adolescents had the choice to be interviewed individually and additional information was sought from parents when needed. Each subject was evaluated separately by one clinician. Before starting the interview the clinician reviewed the consent forms and asked the subjects to sign them. The clinician first administered the K-SADS for diagnosis of OCD and identification of co-occurring conditions. Next, he/she reviewed the DY-BOCS self-report completed by the child (with or without assistance of his/her parents) and then completed the clinician symptom checklist and severity ratings of DYBOCS. This DYBOCS interview was videotaped for inter-rater reliability. The interviewer then completed the other clinician ratings, including the YGTSS and CY-BOCS.

Training of the interviewers

All interviewers were psychiatrists, familiar with all instruments. In order to improve reliability across sites, the DY-BOCS was thoroughly explained to all investigators in an initial startup meeting, problems that arose during the study process were discussed with the research coordinator via telephone or online calls or at scientific meetings to which the investigators attended.

Interrater reliability

Videos from the interviews of four patients were sent to all the study sites and all the investigators at each site were requested to rate the DYBOCS scores. All the questions raised by the investigations were discussed and clarified.

Statistical Analysis

The internal consistency of the DY-BOCS was determined by using Cronbach α to assess the 3 severity items (time, distress, and interference) in each of the dimensions. Convergent validity was assessed with Pearson correlations between the DY-BOCS and the CY-BOCS. To assess the divergent validity of the Turkish version of the DY-BOCS, we calculated correlations between the DY-BOCS subscales and the YGTSS, the CDI, and the CBCL scores for the anxious-depressed and withdrawn dimensions. Large correlations were defined as .50 or greater, medium correlations between .30 and .49, and small correlations

from .10 to .29.⁵⁰ Interrater reliability was determined for a subset of patients using intraclass correlation coefficients. The interviews were video recorded (4 videos), and 6 raters (none of whom was the rater who performed the initial interview) scored them independently. The intercorrelations between each of the different OC symptom dimensions and the level of agreement between self-report and clinician ratings were assessed by Pearson correlation coefficients. All analyses were conducted with SPSS (version 17). All statistical tests were 2 tailed.

Results

All together, 143 subjects (76 male, 67 female; mean age 12.2 years [s.d. = 2.6]) were assessed. There were no significant differences by site based on age ($F(6, 136) = 1.23$; $p = NS$, two-tailed) and gender ($\chi^2(6) = 2.58$, NS). 30.8% of the sample ($N=44$) reported low monthly income, 61.5% ($N=88$) low to medium monthly income and 7.7% ($N=11$) higher income.

Sixty four (44.8% of the sample) subjects lived in large city centers, 53 (37.1%) lived in city centers, 21 (14.7%) in districts or towns, 5 (3.5%) on country side. 88.1% of the children ($N=126$) had siblings. 53.1% of the cases ($N=76$) were the first child of the family. No preceding (before the onset of OC symptoms) stressful life event was reported for 65.7% of the sample ($N=94$) and for 15.4% of the sample ($N=22$), school-related stress factors (test anxiety, being a bullying victim etc) preceding the onset of OC symptoms were reported. The mean scores on each of the DY-BOCS dimensions, on the CY-BOCS, YGTSS, the CDI and the CBCL are presented in Table 1.

Table 2 presents the number of patients presenting symptoms in each of the OC dimensions, as well as the frequency of avoidance behaviors related to each dimension in the Turkish and USA samples.

Reliability

Interrater reliability

The interrater reliability between the DY-BOCS raters was excellent. Intraclass correlation coefficients (ICCs) were > 0.88 for each component of the global severity score of the DY-BOCS.

Internal consistency

The internal consistency across the domains of time, distress, and interference for each dimension was also excellent. Cronbach's alphas were 0.96 for aggressive, 0.94 for sexual/religious, 0.93 for symmetry, 0.95 for contamination, 0.95 for hoarding and 0.94 for miscellaneous dimensions.

Validity

Construct validity

There were no significant differences between the sites with regard to the DY-BOCS total scores ($F(6, 136) = 1.56, p = \text{NS}$, two-tailed). Correlations between each of the DY-BOCS dimensions and the total DY-BOCS scores are presented in Table 3.

With the exception of severity ratings for the hoarding dimension, each of the other severity ratings for specific dimensions, and also the DY-BOCS impairment rating was positively correlated with the DY-BOCS global severity score, with Pearson correlations ranging from 0.18 to 0.93.

Table 4 presents the intercorrelations between each of the different OC symptom dimensions. With a few exceptions, each dimension-specific severity rating was largely independent of the others.

Convergent validity

The correlation between the DY-BOCS total global score and the CY-BOCS total score was high (Pearson $r = 0.55, p < 0.0001$), indicating very good convergent validity of the DY-BOCS total global severity score. Similarly, the correlation between DY-BOCS impairment rating and the CY-BOCS total score (Pearson's $r = 0.45, P < 0.0001$) was significant. The correlations between the DY-BOCS impairment subscale and the obsession (Pearson $r = 0.47, P < 0.0001$) and compulsion (Pearson's $r = 0.35, P < 0.0001$) subscales of the CY-BOCS were also significant.

Divergent validity

Evidence in support of the divergent validity of the DY-BOCS include the independent character of the dimensional severity ratings in Table 4 as well as the differential relationships between the dimensional severity scores and measures of tic severity, as well as CDI and CBCL internalizing, withdrawal and anxious-depressive subscales (Table 5).

Discussion

The DY-BOCS focuses on the assessment of presence and severity of specific OC symptom dimensions as well as estimates of global OCD symptom severity. The current study provides the first analysis of its psychometric properties in a child and adolescent population outside the USA by an independent group of researchers. The results demonstrated that the DY-BOCS is a valid and reliable instrument for assessing OC symptom dimensions in children and adolescents from Turkey.

The current study is of interest since the DYBOCS is capable of advancing the research on the dimensional perspective of OCD. It is important to mention that the study was conducted in a large enough sample ($N=143$) and that the current study is the first child and adolescent study to be undertaken after the original validation study. Furthermore, the study was undertaken as a collaborative joint project across sites and contributed to the awareness of a dimensional approach to the study of OCD, and to the further enhancement of our

understanding of OCD in a youth population especially in a low-to-middle income country context. Therefore, we believe that it increases the knowledge and awareness of OCD in the country.

Avoidance symptoms are commonly reported by OCD patients and the question for avoidance follows each dimension of the symptom checklist and is also an integral part of the severity ratings. Inquiring about avoidance behaviors is useful in understanding the severity of the condition. The frequencies of the avoidance symptoms varied according to the specific dimensions in our sample, with the highest frequency of avoidance being in the contamination dimension.

Frequencies of OC symptom dimensions were similar to the pediatric sample of the original validation study, except for the miscellaneous and the symmetry dimensions, which were lower in the current study. The reasons for these differences are not clear. Early-onset OCD cases have a higher overlap with tic-related OCD. Both groups of patients frequently present with higher frequencies of symmetry, hoarding and miscellaneous dimensions.⁵¹ In the original validation study, data was not shown about the characteristics of the cases and therefore it was not possible to analyze the possible reasons for these differences.

As in the initial validation study,³² the subscales of the DY-BOCS were largely independent from one another and correlated moderately with the DY-BOCS Global Severity score. This suggests that the Turkish version of the DY-BOCS is also capable of measuring the different symptom dimensions of OCD without being confounded by other co-occurring symptoms. These results also confirm the relative independence of the various symptom dimensions of OCD.⁶

Correlations between the DY-BOCS Global Severity scale and the clinician-administered CY-BOCS were significant, suggesting that the DY-BOCS continues to provide valid overall estimates of global OCD symptom severity.³² Correlation coefficient for the DY-BOCS global severity and the CY-BOCS total score was 0.55; this coefficient, although large, was lower than that reported in the original validation study ($r=0.79$).³² It is important to mention that in the original validation study correlation coefficients for adults were higher than the pediatric group.³² Future studies investigating the psychometric properties of the DYBOCS in adult Turkish OCD patients are warranted.

The divergent validity of the DY-BOCS was satisfactory. As expected, the correlations between the DY-BOCS subscales and the CDI and CBCL internalizing symptoms, anxiety and withdrawal subscales ranged from small to moderate and were smaller than the correlations among OCD scales. As seen in table 5, the DY-BOCS Aggression dimension scores showed moderate correlation with the CDI ($r=0.39$) and small correlation with CBCL anxious/depressed subscale ($r=0.19$). Aggression, symmetry and contamination dimensions showed small correlations with the CBCL internalizing subscale; symmetry dimension also had a mild correlation with the withdrawal subscale. These results are partially in agreement with those reported in the original validation study³² where the authors found that the aggression dimension had the strongest correlations with the HAM-D (Hamilton-Depression

Scale) and HAM-A (Hamilton-Anxiety Scale) scores. The differences may be due to the use of different instruments in the two studies.

Although highly significant, the correlations between the DYBOCS impairment subscale and the obsession and compulsion CYBOCS subscales were not very high (0.47 and 0.35, respectively). The impairment subscale was an innovation included as part of the DYBOCS because of the clinical observation that each patient experience the impact caused by the symptoms in their lives very differently. For instance, some patients have mild symptoms with very high scores on the impairment DYBOCS subscale while others have moderate to severe symptoms and low impairment scores. The lower correlations might be due to the fact that the CY-BOCS does not have an overall impairment score.

There were positive correlations between the aggressive and the sexual-religious dimensions. Aggressive, sexual and religious obsessions tend to co-occur and among the 4-OCD factors, aggression and sexual/religious obsessions were counted together under “forbidden thoughts” factor.⁵² The miscellaneous dimension comprises several different OC symptoms (eg, about disease, superstitious fears/behaviors, obsessions about food, and pathologic grooming behaviors such as skin picking or trichotillomania).³¹ This dimension showed moderate correlations with the aggression, sexual/religious and the hoarding dimensions of the DY-BOCS, suggesting that some of the symptoms included in the miscellaneous dimension might be associated with these dimensions. It is unclear whether some symptoms included in the miscellaneous dimension may constitute one or more independent dimensions.

After completing the symptom checklist and reviewing it with the clinician, most of the subjects reported that their knowledge about OCD had increased, as did their awareness about the concepts, such as frequency, severity, interference, avoidance and the impairment due to the symptoms. Therefore, it is reasonable to conclude that the DYBOCS is a valuable tool not only for research purposes but also for clinicians, since it can provide information on obsessions and compulsions that had not been previously reported by the patient.

Limitations

The findings reported in the study need to be considered in the context of a number of limitations. First, the sample was comprised of children and adolescents in Turkey and cannot be generalized to the characteristics of adult OCD population in the country or elsewhere. We could therefore compare and contrast our findings with one study involving US children to date. Second, inter-rater reliability was determined for a subset of subjects in view of challenges given the length of administration of DY-BOCS clinician interviews. Third, as in the original validation study, we did not evaluate the test-retest reliability of the DY-BOCS self-report. Therefore, we couldn't assess the variability of the instrument which limits its use as an outcome measure in treatment studies. Fourth, earliest age at onset was 1 year, which was probably a memory bias, but such retrospective recall bias is well known and cannot be clinically ignored.

As mentioned in the original validation paper, one limitation of the DY-BOCS is the time required for administration of the instrument. According to the original validation study, an average patient needs approximately 40 minutes to complete the interview.³²

Conclusions

OCD is a serious disabling disorder with observed core symptoms consistent across cultures.⁵³ The results of the present study confirm that the DYBOCS has excellent psychometric properties in a large clinical sample of children and adolescents in Turkey.

Future studies should better investigate the psychometric properties of the DY-BOCS in nonclinical populations and also in adult OCD patients. It would also be interesting to investigate possible differences in OC symptom frequencies in different countries, trying to better understand possible cultural effects on symptom manifestation.

Acknowledgments

Authors were at the institutions listed on the title page at the time of the research. Y Yulaf and Y Yazgan are currently in private practice. AB Ayaz is currently at Marmara University. S Ba gül is at Hasan Kalyoncu University.

Funding

The research was funded in part by Fogarty/NIH ICOHRTA grant 5D43TW005807 and Dr. AS Guler was supported by the NIH/Fogarty International Center MHDD Research Training Program (5D43TW005807, Dr. K. Munir, at Boston Children's Hospital in the Division of Developmental Medicine).

References

1. Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Kalikow K, Sceery W, Shaffer D. Obsessive compulsive disorder in adolescence: An epidemiological study. *J Am Acad Child Adolesc Psychiatry*. 1998; 27:764–71. [PubMed: 3264280]
2. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 30:327–37. [PubMed: 16412548]
3. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol Psychiatry*. 2010; 15:53–63. [PubMed: 18725912]
4. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM4)*. 4. Washington, DC: American Psychiatric Press; 1994.
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM5)*. 5. Washington, DC: American Psychiatric Press; 2013.
6. Mataix-Cols D, do Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. *Am J Psychiatry*. 2005; 162:228–8. [PubMed: 15677583]
7. Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Philips KA, Stein DJ. Obsessive compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. *Depression and Anxiety*. 2010; 27:507–27. [PubMed: 20217853]
8. Summerfeldt LJ, Kloosterman PH, Antony MM, Swinson RP. Examining an obsessive-compulsive core dimensions model: Structural validity of harm avoidance and incompleteness. *Journal of Obsessive-Compulsive and Related Disorders*. 2014; 3:83–94.

9. Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. *Am J Psychiatry*. 2008; 165(12):1532–42. [PubMed: 18923068]
10. Stewart SE, Rosario MC, Brown TA, Carter AS, Leckman JF, Sukhodolsky D, Katsovitch L, King R, Geller D, Pauls DL. Principal components analysis of obsessive-compulsive disorder symptoms in children and adolescents. *Biol Psychiatry*. 2007; 61(3):285–91. [PubMed: 17161383]
11. Mataix-Cols D, Nakatani E, Micali E, Heyman I. Structure of obsessive-compulsive symptoms in pediatric OCD. *J Am Acad Child Adolesc Psychiatry*. 2008; 47(7):773–8. [PubMed: 18344900]
12. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. *Am J Psychiatry*. 1999; 156:1409–16. [PubMed: 10484953]
13. Summerfeldt LJ, Richter MA, Antony MM, Swinson RP. Symptom structure in obsessive-compulsive disorder: a confirmatory factor analytic study. *Behav Res Ther*. 1999; 37:297–311. [PubMed: 10204276]
14. Hasler G, Lasalle-Ricci VH, Ronquillo JG, Crawley SA, Cochran LW, Kazuba D, Greenberg BD, Murphy DL. Obsessive-compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. *Psychiatry Res*. 2005; 135:121–32. [PubMed: 15893825]
15. Mataix-Cols D, Rauch SL, Baer L, Eisen JL, Shera DM, Goodman WK, Rasmussen SA, Jenike MA. Symptom stability in adult obsessive-compulsive disorder: Data from a naturalistic two-year follow-up study. *Am J Psychiatry*. 2002; 159:263–8. [PubMed: 11823269]
16. Rufer M, Grothausen A, Mass R, Peter H, Hand I. Temporal stability of symptom dimensions in adult patients with obsessive-compulsive disorder. *J Affect Disord*. 2005; 88:99–102. [PubMed: 16040125]
17. Alvarenga PG, do Rosário MC, Batistuzzo MC, Diniz JB, Shavitt RG, Duran FL, Dougherty DD, Bressan RA, Miguel EC, Hoexter MQ. Obsessive-compulsive symptom dimensions correlate to specific gray matter volumes in treatment-naïve patients. *J Psychiatr Res*. 2012; 46(12):1635–42. [PubMed: 23040160]
18. van den Heuvel OA, Remijnse PL, Mataix-Cols D, Vrenken H, Groenewegen HJ, Uylings HB, van Balkom AJ, Veltman DJ. The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. *Brain*. 2009; 132:853–68. [PubMed: 18952675]
19. Mataix-Cols D, Cullen S, Lange K, Zelaya F, Andrew C, Amaro E, Brammer MJ, Williams SC, Speckens A, Phillips ML. Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. *Biol Psychiatry*. 2003; 53:482–93. [PubMed: 12644353]
20. Mataix-Cols D, Wooderson S, Lawrence N, Brammer MJ, Speckens A, Phillips ML. Distinct neural correlates of washing, checking and hoarding symptom dimensions in obsessive-compulsive disorder. *Arch Gen Psychiatry*. 2004; 61:564–76. [PubMed: 15184236]
21. Rauch SL, Dougherty DD, Shin LM, Alpert NM, Manzo P, Leahy L, Fischman AJ, Jenike MA, Baer L. Neural correlates of factor-analyzed OCD symptom dimensions: a PET study. *CNS Spectr*. 1998; 3:37–43.
22. Miguel EC, Leckman JF, Rauch S, do Rosario-Campos MC, Hounie AG, Mercadante MT, Chacon P, Pauls DL. Obsessive-compulsive disorder phenotypes: implications for genetic studies. *Mol Psychiatry*. 2005; 10:258–75. [PubMed: 15611786]
23. Alsobrook JP II, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL. Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. *Am J Med Genet*. 1999; 88:669–75. [PubMed: 10581488]
24. Leckman JF, Pauls DL, Zhang H, Rosario-Campos MC, Katsovich L, Kidd K, Pakstis AJ, Alsobrook JP, Robertson MM, McMahon WM, Walkup JT, van de Wetering BJ, King RA, Cohen DJ. Tourette Syndrome Association International Consortium for Genetics. Obsessive-compulsive symptom dimensions in affected sibling pairs diagnosed with Gilles de la Tourette syndrome. *Am J Med Genet*. 2003; 116:60–8. [PubMed: 12497616]
25. Zhang H, Leckman JF, Tsai C-P, Kidd KK, Rosario Campos MC. The Tourette syndrome association international consortium for genetics. Genome wide scan of hoarding in sibling pairs

- both diagnosed with Gilles de la Tourette syndrome. *Am J Hum Genet.* 2002; 70:896–904. [PubMed: 11840360]
26. Cavallini MC, Di Bella D, Siliprandi F, Malchiodi F, Bellodi L. Exploratory factor-analysis of obsessive–compulsive patients and association with 5-HTTLPR polymorphism. *Am J Med Genet.* 2002; 114:347–53. [PubMed: 11920862]
 27. Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L. Obsessive–compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. *Psychother Psychosom.* 2002; 71:255–62. [PubMed: 12207105]
 28. Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P. Hoarding and treatment response in 38 nondepressed subjects with obsessive–compulsive disorder. *J Clin Psychiatry.* 1998; 59:420–5. [PubMed: 9721822]
 29. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J. Long-term follow-up and predictors of clinical outcome in obsessive–compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. *J Clin Psychiatry.* 2001; 62:535–40. [PubMed: 11488364]
 30. Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, Tarlow G, Bystritsky A. Obsessive–compulsive hoarding: symptom severity and response to multimodal treatment. *J Clin Psychiatry.* 2002; 63:21–7. [PubMed: 11838621]
 31. Pertusa A, Jaurrieta N, Reala E, Alonso P, Buena B, Segalà C, Jiménez-Murcia S, Mataix-Cols D, Menchón JM. Spanish adaptation of the Dimensional Yale-Brown Obsessive-Compulsive Scale. *Compr Psychiatry.* 2010; 51:641–8. [PubMed: 20965311]
 32. Rosario-Campos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y, Findley D, Katsovich L, Scahill L, King RA, Woody SR, Tolin D, Hollander E, Kano Y, Leckman JF. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. *Mol Psychiatry.* 2006; 11(5):495–504. [PubMed: 16432526]
 33. Li Y, Marques L, Hinton DE, Wang Y, Xiao Z-P. Symptom Dimensions in Chinese Patients with Obsessive-Compulsive Disorder. *CNS Neuroscience & Therapeutics.* 2009; 15:276–82. [PubMed: 19691547]
 34. Harsanyi A, Csigo K, Demeter G, Rajnai C, Nemeth A, Racsmany M. Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test. *Psychiatr Hung.* 2009; 24(1):18–59. [PubMed: 19542567]
 35. Kim HW, Kang JI, Kim SJ, Jhung K, Kim EJ, Kim SJ. A Validation Study of the Korean-Version of the Dimensional Obsessive-Compulsive Scale. *J Korean Neuropsychiatr Assoc.* 2013; 52(3): 130–42.
 36. Kano Y, Kono T, Shishikura K, Kuwabara H, Ohta M, do Rosario MC. Obsessive-compulsive symptom dimensions in Japanese Tourette syndrome subjects. *CNS.* 2010; 15:296–303.
 37. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for affective disorders and schizophrenia for school-age children—present and lifetime version (KSADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry.* 1997; 36:980–8. [PubMed: 9204677]
 38. Gökler B, Ünal F, Pehlivan Türk B, Kültür EÇ, Akdemir D, Taner Y. Okul Ça ı Çocukları için Duygulanım Bozuklukları ve izofreni Görü me Çizelgesi- imdi ve Ya am Boyu ekli-Türkçe Uyarlamasının Geçerlik ve Güvenirli i. *Çocuk ve Gençlik Ruh Sa lı ı Dergisi.* 2004; 11(3):109–16.
 39. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF. Children’s Yale-Brown Obsessive-Compulsive Scales: reliability and validity. *J Am Acad Child Adolesc Psychiatry.* 1997; 36(6):844–52. [PubMed: 9183141]
 40. Yucelen GA, Rodopman-Arman A, Topcuoglu V, Yazgan MY, Fi ek G. Interrater reliability and clinical efficacy of Children’s Yale-Brown Obsessive-Compulsive Scale in an outpatient setting. *Compr Psychiatry.* 2006; 47:48–53. [PubMed: 16324902]
 41. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry.* 1989; 28:566–73. [PubMed: 2768151]

42. Achenbach, TM.; Rescorla, LA. Manual for the ASEBA School-Age Forms & Profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
43. Dümenci L, Erol N, Achenbach TM, Simsek Z. Measurement Structure of the Turkish Translation of the Child Behavior Checklist Using Confirmatory Factor Analytic Approaches to Validation of Syndromal Constructs. *J Abnorm Child Psychol.* 2004; 32(3):335–40. [PubMed: 15228181]
44. Nauta MH, Scholing A, Rapee RM, Abbott M, Spence SH, Waters A. A parent-report measure of children's anxiety: psychometric properties and comparison with child-report in a clinic and normal sample. *Behavior Research and Therapy.* 2004; 42:813–39.
45. Ebesutani C, Bernstein A, Nakamura BJ, Chorpita BF, Weisz JR. A Psychometric Analysis of the Revised Child Anxiety and Depression Scale—Parent Version in a Clinical Sample. *J Abnorm Child Psychol.* 2010; 38:249–60. [PubMed: 19830545]
46. Linyan S, Kai W, Fang F, Yi S, Xueping G. Reliability and validity of the screen for child anxiety related emotional disorders (SCARED) in Chinese children. *J Anxiety Disord.* 2008; 22:612–21. [PubMed: 17628391]
47. Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. *J Am Acad Child Adolesc Psychiatry.* 2002; 41(9):1061–9. [PubMed: 12218427]
48. Kovacs M. The children's depression inventory (CDI). *Psychopharmacol Bull.* 1985; 21:995–8. [PubMed: 4089116]
49. Öy B. Çocuklar için depresyon ölçme ölçeği: geçerlik ve güvenirlik çalışması. *Türk Psikiyatri Dergisi.* 1991; 2:132–6.
50. Cohen, J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977. Revised edition
51. Leckman JF, Bloch MH, King RA. Symptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective. *Dialogues Clin Neurosci.* 2009; 11(1):21–33. [PubMed: 19432385]
52. Bloch MH, Craiglow BG, Landeros-Weisenberger A, Dombrowski PA, Panza KE, Peterson BS, Leckman JF. Predictors of Early Adult Outcomes in Pediatric-Onset Obsessive-Compulsive Disorder. *Pediatrics.* 2009; 124(4):1085–1093. [PubMed: 19786445]
53. Pellanti S. Transcultural observations of obsessive-compulsive disorder. *Am J Psychiatry.* 2008; 165:169–70. [PubMed: 18245183]

Table 1

Mean scores on the DY-BOCS, the CY-BOCS, the YGTSS, the CDI and the CBCL scales

	Subjects (N)	Mean (s.d.)	Range
DY-BOCS global score	143	18.6 (4.9)	8–28
DY-BOCS dimensions			
Aggression	143	4.2 (4.5)	0–14
Sexual/religious	143	4.7 (4.6)	0–15
Symmetry	143	5.7 (3.8)	0–14
Contamination	143	5.6 (4.5)	0–15
Hoarding	143	1.7 (2.9)	0–14
Miscellaneous	143	2.6 (3.7)	0–13
Total symptom score	143	9.5 (2.4)	3–15
DY-BOCS impairment	143	9.1 (2.7)	2–14
CY-BOCS total score	135	24.9 (6.7)	7–40
CY-BOCS obsessions	135	12.7 (3.8)	0–20
CY-BOCS compulsions	135	12.1 (3.9)	0–20
YGTSS total score	54	16.2 (11.1)	0–48
YGTSS motor tics	54	10.1 (5.9)	0–22
YGTSS vocal tics	54	5.1 (5.9)	0–19
CDI	120	14.3 (8.2)	1–46
CBCL total T score	127	63.7 (9.1)	41–84
CBCL internalizing	127	65.7 (9.7)	41–95
CBCL externalizing	127	60.6 (9.0)	34–79
CBCL withdrawal	127	60.7 (9.2)	50–90
CBCL somatic	127	61.9 (9.4)	50–90
CBCL anxious	127	68.0 (10.2)	50–96
CBCL social problems	127	62.4 (8.6)	50–93
CBCL thought problems	127	65.3 (9.0)	50–90
CBCL attention problems	127	58.2 (6.7)	50–80
CBCL delinquency	127	59.4 (6.4)	50–74
CBCL aggression	127	62.3 (9.3)	50–87

DY-BOCS= Dimensional Yale-Brown Obsessive-Compulsive Scale, CY-BOCS= Children's Yale-Brown Obsessive-Compulsive Scale, YGTSS= Yale Global Tic Severity Scale, CDI= Children's Depression Inventory, CBCL (6-18)= Child Behavior Checklist for ages 6 to 18

Table 2

The frequency of symptom dimensions and avoidance behaviors in the Turkish and the USA samples

	Turkish Sample (N=143) DY-BOCS		USA sample (N=59)* DY-BOCS	
	Symptom dimensions	Avoidance behaviors	Symptom dimensions	Avoidance behaviors
Aggression	61 (42.7%)	28.7%	33 (56%)	32%
Sexual/religious	62 (43.4%)	24%	20 (34%)	25%
Symmetry	84 (58.7%)	19.6%	51 (86%)	52%
Contamination	76 (53.1%)	43.4%	36 (61%)	54%
Hoarding	29 (20.3%)	4.2%	22 (37%)	15%
Miscellaneous	28 (19.6%)	12.6%	50 (85%)	54%

* Data comes from the original validation study of the DYBOCS (Rosario-Campos et al., 2006). There is no statistical comparison between the Turkish and the USA sample.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Correlations between the dimensional DY-BOCS global score and the symptom severity ratings for each dimension, the components of the global severity ratings and the impairment rating

	Pearson's r	p
Dimensions		
Aggression	0.43	<0.0001
Sexual/religious	0.38	<0.0001
Symmetry	0.20	0.014
Contamination	0.21	0.009
Hoarding	0.15	NS
Miscellaneous	0.18	0.024
Global Severity		
Time	0.77	<0.0001
Distress	0.80	<0.0001
Interference	0.79	<0.0001
Impairment Rating	0.93	<0.0001

Intercorrelations between estimates of current symptom severity within each of the dimensional components of the DY-BOCS

Table 4

Dimensions	Sexual/religious	Symmetry	Contamination	Hoarding	Miscellaneous
Aggression	0.54**	0.06	-0.04	0.15	0.24**
Sexual/religious		-0.10	-0.14	0.10	0.25**
Symmetry			-0.06	0.12	0.12
Contamination				0.07	0.06
Hoarding					0.28**

* Correlation is significant at the .05 level (2-tailed).

** Correlation is significant at the .01 level (2-tailed).

Correlations between each of the DY-BOCS dimensions and scores of the YGTSS, CDI and CBCL internalizing, withdrawal and anxious subscales

Table 5

Dimensions	YGTSS	CDI	CBCL internalizing	CBCL withdrawal	CBCL anxious
Aggression	0.01	0.36**	0.18*	0.14	0.19*
Sexual/religious	-0.05	0.17	0.03	-0.03	0.11
Symmetry	0.06	0.07	0.21*	0.25**	0.14
Contamination	-0.05	0.02	0.19*	0.15	0.15
Hoarding	-0.04	0.12	0.06	0.11	0.04
Miscellaneous	-0.10	0.25**	0.16	0.10	0.14

* Correlation is significant at the .05 level (2-tailed).

** Correlation is significant at the .01 level (2-tailed).

YGTSS: Yale Global Tic Severity Scale; CDI: Children's Depression Inventory; CBCL (6-18): Child Behavior Checklist for ages 6 to 18